SCHEMBL471689

SCHEMBL471689

CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2C=O

nearest known ligand 0.62

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
F2R P25116 20/20 0.62
ABCB11 O95342 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
CHRM1 P11229 1/20 0.59
SLC6A2 P23975 1/20 0.59
GPR183 P32249 1/20 0.59
OPRM1 P35372 1/20 0.59
KCNH2 Q12809 1/20 0.59
GPR35 Q9HC97 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199850 1.00 F2R (0.62) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL14203695 1.00 F2R (0.62) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL13610978 0.91 F2R (0.62) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL471191 0.90 F2R (0.53) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL12213125 0.88 F2R (0.58) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL14203708 0.88 F2R (0.58) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL471183 0.86 F2R (0.56) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL13199852 0.86 F2R (0.56) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL13090681 0.86 F2R (0.56) F2RABCB11ADORA3CHRM1SLC6A2
SCHEMBL13603617 0.86 F2R (0.58) F2RABCB11ADORA3CHRM1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046804-B1 Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2-yl]methyl} phosphonate used in the synthesis of himbacine analogs MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
EP-2196454-B1 EXO-AND DIASTEREO-SELECTIVE SYNTHESES OF HIMBACINE ANALOGS MERCK SHARP & DOHME (US) 2014-08-27 EP disclosed
EP-1846385-B1 AN EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS MERCK SHARP & DOHME (US) 2013-07-31 EP disclosed
EP-2196468-B1 Exo-and diastereo-selective syntheses of himbacine analogs MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-8329905-B2 Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate MERCK SHARP & DOHME CORP. (US) 2012-12-11 US disclosed
US-20120302745-A1 EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS THIRUVENGADAM TIRUVETTIPURAM K (US) 2012-11-29 US disclosed
US-20120296093-A1 EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS TOPROL ACQUISITION LLC 2012-11-22 US disclosed
US-8273790-B2 Exo-selective synthesis of himbacine analogs SCHERING CORPORATION (US) 2012-09-25 US disclosed
US-8258319-B2 Exo- and diastereo- selective synthesis of himbacine analogs SCHERING CORPORATION (US) 2012-09-04 US disclosed
US-20120142914-A1 EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS TOPROL ACQUISITION LLC 2012-06-07 US disclosed
US-20090281321-A1 EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS SCHERING CORPORATION 2009-11-12 US disclosed
US-7605275-B2 Cyclization of 1-(1-(diphenylaminocarbonyl-vinyl-)ethyl-oxycarbonyl-vinyl-),5-nitro-)cyclohex-1-ene by heating in a solvent to form an trans-(5,6)ring junction and an endoisomer(cis) isomer of 3-(oxo),6-(nitro),9-diphenylamido-perhydro-4,4a-didehydronaphtho(2,3)furan SCHERING CORPORATION (US) 2009-10-20 US disclosed
US-20090203936-A1 SYNTHESIS OF 3-(5-NITROCYCLOHEX-1-ENYL) ACRYLIC ACID AND ESTERS THEREOF SCHERING CORPORATION 2009-08-13 US disclosed
US-7553987-B2 Synthesis of 3-(5-nitrocyclohex-1-enyl) acrylic acid and esters thereof SCHERING CORPORATION (US) 2009-06-30 US disclosed
US-7541471-B2 Synthesis of himbacine analogs SCHERING CORPORATION (US) 2009-06-02 US disclosed
US-7541471-B2 Synthesis of himbacine analogs SCHERING CORPORATION (US) 2009-06-02 US disclosed
US-20080009651-A1 Synthesis of 3-(5-nitrocyclohex-1-enyl) acrylic acid and esters thereof MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
WO-2008005348-A1 SYNTHESIS OF DIETHYL{ I5' (3 -FLUOROPHENYL) -PYRIDINE-2-YL] METHYL} PHOSPHONATE USED IN THE SYNTHESIS OF HIMBACINE ANALOGS SCHERING CORPORATION (US) 2008-01-10 WO disclosed
US-20080004449-A1 Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate TOPROL ACQUISITION LLC 2008-01-03 US disclosed
US-20080004449-A1 Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate TOPROL ACQUISITION LLC 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203936-A1 SYNTHESIS OF 3-(5-NITROCYCLOHEX-1-ENYL) ACRYLIC ACID AND ESTERS THEREOF PPOX, PNPO, DAO F2R 971/4885ABCB11 4124/4885ADORA3 1258/4885
US-20080004449-A1 Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate F2, F2R, PTAFR F2R 2/4885ABCB11 3977/4885ADORA3 53/4885
US-20080009651-A1 Synthesis of 3-(5-nitrocyclohex-1-enyl) acrylic acid and esters thereof PPOX, PNPO, DAO F2R 971/4885ABCB11 4124/4885ADORA3 1258/4885
US-20120296093-A1 EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS EDNRA, EDNRB, NMBR F2R 30/4885ABCB11 2482/4885ADORA3 145/4885
US-20120302745-A1 EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS CHKB, BDKRB1, EDNRB F2R 70/4885ABCB11 3512/4885ADORA3 146/4885
US-20090281321-A1 EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS EDNRA, EDNRB, NMBR F2R 24/4885ABCB11 2458/4885ADORA3 166/4885
US-20120142914-A1 EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS CHKB, BDKRB1, EDNRB F2R 70/4885ABCB11 3512/4885ADORA3 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.